C-H3U4microRNA, oligonucleotides, MIR-Discovery
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Identify therapeutic targets linked to longevity-associated diseases and challenging or undruggable targets, then support development of personalized microRNA therapies.
Target-identification and drug-discovery platform for developing microRNA-based oligonucleotides against disease-linked targets.
Described as Mirscience Therapeutics' platform for identifying disease-linked therapeutic targets and developing microRNA-based oligonucleotides.
Develop a microRNA-based therapeutic molecule with regenerative and hypertrophic effects on muscle mass for diseases causing atrophy and frailty, including muscle atrophy, sarcopenia, cachexia induced by cancer, and muscle frailty.
MicroRNA-based oligonucleotide therapy identified through Mirscience Therapeutics' MIR-Discovery platform.
Listed as the company's first molecule in its pipeline.
Company describes MT-29 as having regenerative and hypertrophic effects on muscle mass; no clinical results are supplied.
Identify microRNAs with therapeutic potential for osteosarcopenia by examining shared regulators of sarcopenia and osteoporosis hallmarks.
Review and synthesis of evidence on microRNAs regulating bone and skeletal muscle decline, including miR-29b, miR-128, miR-21, miR-199b, and miR-672.
2024 publication in Current Osteoporosis Reports summarizing candidate microRNA targets for osteosarcopenia therapy.
The review identified miR-29b and miR-128 as potential inhibitor targets, miR-199b as a possible analogue-restoration target, and miR-672 as a candidate protective therapy for skeletal muscle and bone.